7 月 23 日，CDE 官网显示，百济神州BGB-45035 片获批临床，用于治疗类风湿性关节炎。这是继特应性皮炎和结节性痒疹后，BGB-45035 获批的第三项临床。来源：CDE 官网BGB-45035 是一款靶向白细胞介素 1 受体相关激酶4（IRAK4）的 蛋白降解剂（CDAC）。据百济介绍，BGB-45035 具有同类最佳（BIC）潜力，在临床前模型中，相比 KT474，BGB-...
Source Link7 月 23 日，CDE 官网显示，百济神州BGB-45035 片获批临床，用于治疗类风湿性关节炎。这是继特应性皮炎和结节性痒疹后，BGB-45035 获批的第三项临床。来源：CDE 官网BGB-45035 是一款靶向白细胞介素 1 受体相关激酶4（IRAK4）的 蛋白降解剂（CDAC）。据百济介绍，BGB-45035 具有同类最佳（BIC）潜力，在临床前模型中，相比 KT474，BGB-...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.